SAN DIEGO - La Jolla Pharmaceutical Company (Nasdaq: LJPC) (La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today …
La Jolla Pharmaceutical Company LJPC was a big mover last session, as the company saw its shares rise over 11% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This …
After industry watchers at J.P. Morgan downgraded shares to an underweight rating, La Jolla Pharmaceutical Company (NASDAQ ... When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the …
SAN DIEGO, Dec. 21, 2017 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC) (the Company or La Jolla) today announced that the U.S. Food and Drug Administration (FDA) has approved GiaprezaTM (angiotensin II) …
SAN DIEGO, March 15, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC) (La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from …